Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report

Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report

Introduction: Neoadjuvant or perioperative treatment, including an immune checkpoint inhibitor (ICI), has emerged as a new standard for patients with resectable stage III NSCLC. Nevertheless, approximately 20% of patients who start neoadjuvant chemo-immunotherapy will not undergo definitive surgery....

Full description

Saved in:
Bibliographic Details
Main Authors: Sabine Raimann, MD, Sämi Schär, PhD, Stefanie Hayoz, PhD, Matthias Guckenberger, MD, Tobias Finazzi, MD, PhD, Isabelle Opitz, MD, Sabine Schmid, MD, Michael Mark, MD, Alfredo Addeo, MD, Laetitia A. Mauti, MD, PhD, Daniel C. Betticher, MD, Hans-Beat Ris, MD, Roger Stupp, MD, Alessandra Curioni-Fontecedro, MD, Solange Peters, MD, PhD, Martin Früh, MD, Sacha I. Rothschild, MD, PhD, Miklos Pless, MD, David König, MD
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:JTO Clinical and Research Reports
Subjects:
Resectable NSCLC
Neoadjuvant treatment
Definitive surgery
Progression
Salvage treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000505
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000505

Similar Items